Investigators from Shanghai, China, report responses above 90% by using levantinib and tislelizumab to treat patients with a ...
Researchers at the University of Toronto see a future where a single injection under the eyelid could replace months of daily ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback